

---

Marija Miletić<sup>1</sup>, Miloš Stojanović<sup>1</sup>, Mirjana Stojković<sup>1</sup>, Biljana Nedeljković Beleslin<sup>1</sup>, Milina Tančić Gajić<sup>1</sup>, Jasmina Ćirić<sup>1</sup>, Miloš Žarković<sup>1</sup>

## GRANULOMATOZA SA POLIANGITISOM – MOGUĆI ENDOKRINI ASPEKTI

**Apstrakt:** Granulomatoza sa poliangitisom (GPA), ranije poznata kao Wegener-ova granulomatoza, je nekrotizirajući vaskulitis krvnih sudova male i srednje veličine koje karakteriše difuzno zapaljenje vaskularnih struktura i perivaskularna i ekstravaskularna granulomatoza. U svom sistemskom obliku, GPA dominantno zahvata uho, nos i grlo, uz zahvaćenost pluća i bubrega sa tipično brzo progresivnim nekrotizirajućim glomerulonefritisom sa ekstrakapilarnim polumesecima, dok se odsustvo oštećenja bubrega u vreme postavljanja dijagnoze definiše kao ograničen oblik GPA prognostički povoljnijeg toka (1, 2). Antineutrofilna citoplazmatska antitela (c-ANCA) sa specifičnošću za proteinazu 3 (PR3) predstavljaju biohemijsku dijagnostičku odrednicu. Detektuju se u 90% generalizovanih oblika i u oko 50% ograničenih oblika granulomatoze sa poliangitisom (1, 2).

U odsustvu lečenja GPA je oboljenje progresivne evolucije. Sistemska kortikosteroidna terapija i imunosupresivna terapija su značajno izmenili prognostički aspekt oboljenja. O endokrinim oboljenjima povezanim sa GPA objavljeno je tek nekoliko sporadičnih zapažanja. Predstavljamo slučaj 39-godišnjeg muškarca sa autoimunim poremećajem štitaste žlezde koje se eksprimovalo 8 godina nakon inicijalne dijagnoze granulomatoznog poliangitisa.

**Ključne reči:** granulomatoza sa poliangitisom, autoimuna oboljenja štitaste žlezde, antineutrofilna citoplazmatska antitela, vaskulitis malih krvnih sudova

### *Uvod*

Granulomatoza sa poliangitisom (GPA), ranije poznata kao Wegener-ova granulomatoza, je nekrotizirajući vaskulitis krvnih sudova male i srednje veličine koje

---

<sup>1</sup> Univerzitetska klinika za endokrinologiju, dijabetes i bolesti metabolizma, Klinički centar Srbije, drmariamiletic@gmail.com

karakteriše difuzno zapaljenje vaskularnih struktura i perivaskularna i ekstravaskularna granulomatoza. U svom sistemskom obliku, GPA dominantno zahvata uho, nos i grlo, uz zahvaćenost pluća i bubrega sa tipično brzo progresivnim nekrotizirajućim glomerulonefritisom sa ekstrakapilarnim polumesecima, dok se odsustvo oštećenja bubrega u vreme postavljanja dijagnoze definiše kao ograničen oblik GPA prognostički povoljnijeg toka (1, 2). Antineutrofilna citoplazmatska antitela (c-ANCA) sa specifičnošću za proteinazu 3 (PR3) predstavljaju biohemijsku dijagnostičku odrednicu. Detektuju se u 90% generalizovanih oblika i u oko 50% ograničenih oblika granulomatoze sa poliangitisom (1, 2).

U odsustvu lečenja GPA je oboljenje progresivne evolucije. Sistemska kortikosteroidna terapija i imunosupresivna terapija su značajno izmenili prognostički aspekt oboljenja. O endokrinim oboljenjima povezanim sa GPA objavljeno je tek nekoliko sporadičnih zapažanja.

### ***Prikaz slučaja***

M. N., 39 godina, 8 godina ranije hospitalizovan u Klinici za pulmologiju, nakon radiografski uočenih promena u plućima obostrano. Tegobe su se javile u vidu krvarenja iz nosa, migrirajućeg bola u zglobovima, malaksalosti, otežanog gutanja čvrste hrane. ORL pregledom dijagnostikovao erozivni rinitis, a u brisu nosa detektovan *Staphylococcus aureus*. Prisutna mikrohematurija u sedimentu urina. MDCT grudnog koša pokazao je multiple fokalne promene promera do 30 mm, desno hilobazalno zone kondenzacije parenhima po tipu subsegmentne atelektaze. Učinjene imunološke analize koje su potvrdile Wegener-ovu granulomatozu, cANCA 1:320, antiPR3At 100. Angiotenzin konvertujući enzim, tumorski markeri, serološki virusni markeri su bili u granicama referentnih vrednosti. Uvedena je terapija pulsnom dozama ciklofosfamida i glukokortikoida, primio je 6 ciklusa, nakon čega je započeta oralna terapija. Kontrolne vizuelizacije pluća pokazale su progresivan tok, nakon čega je pacijent primio dva ciklusa terapije imunoglobulinima, a dalje lečenje nastavljeno je Metotreksat tbl per os, uz folnu kiselinu i oralnu glukokortikoidnu terapiju uz postepeno smanjivanje doze. Zbog porasta PR3At, ANCA c i CRP, uz stacionaran nalaz NMR pluća i odsustvo tegoba, učinjena je pozitronska emisiona tomografija celog tela (FDG PET/CT), koja je pokazala pojačano vezivanje FDG u štitastoj zlezdi, difuzno i umereno (SUV max 4.7 u desnom, SUV max 3.3 u levom lobusu, diskretno vezivanje u nivou multiplih promena u plućima obostrano (SUV max do 1.9, u okolnom plućnom tkivu SUV max 1.1). U porodičnoj anamnezi majka je imala tireoidektomiju zbog strume. EHO štitaste žlezde: pravilno položena tiroidea, uobičajene veličine, pseudoseptirana, heterogena, izmenjena po tipu hroničnog tiroiditisa, bez izdvajanja cističnih ili solidnih promena. Biohemijske analize bile su uredne, kao i procena bubrežne funkcije. Hormonske analize: tiroitronni hormoni (TSH) 4,4 m IU/L, slobodni tiroksin (FT4) 9,9 ng/l,

antitireoperoksidazna antitela 37,09 IU/ml, antitireoglobulinska antitela (AntiTg at) 124,2 IU/ml, folikulostimulišući hormon (FSH) 2,6 IU/L, luteotropni hormon (LH) 3,2 IU/L, testosteron (T) 13,3 nmol/l, PRL 314 mIU/L, dehidroepiandrosteron (DHEA-S) 5,7 mmol/l, vitamin D 95 nmol/l, PTH 50 ng/l.

Uvedena je terapija preparatima inozitola, uz praćenje tiroidne funkcije na 3 meseca.

## ***Diskusija***

Granulomatoza sa poliangitisom (GPA, Wegenerova granulomatoza) je idiopatska sistemska bolest koja se klasično manifestuje kao trijada zahvaćenosti gornjeg i donjeg respiratornog trakta sa glomerulonefritisom (3). Najčešći simptomi su nespecifični i podrazumevaju febrilnost, malaksalost, kašalj, gubitak težine, bol u grudima i hemoptizije. Prevalenca WG procenjena je na 23,7–156,5: 1.000.000 (4, 5) sa godišnjom incidencom 3,0–14,4: 1.000.000 (6,7).

Antineutrofilna citoplazmatska autoantitela (ANCA) su serološka odrednica GPA. ANCA su uglavnom usmerene protiv proteinaze 3 (PR3-ANCA). Sinusitis je najčešća inicijalna prezentacija kod oko polovine do dve trećine pacijenata sa VG (3). Zahvaćenost pluća i bubrega su klasične manifestacije WG, a očne manifestacije javljaju se u 28% do 58% pacijenata sa WG. Ostale prilično neuobičajene prezentacije WG uključuju pljuvačne žlezde, zahvaćenost kože, gastrointestinalnog trakta i srca. Oboljenje se može javiti u bilo kom uzrastu, ali vrhunac incidencije je u ranom srednjem dobu. Nešto češće se javlja u muškaraca. Nelečena, bolest je povezana sa veoma lošim prognozama. Iako se ANCA nalaze u većini pacijenata sa WG, histopatološka analiza i dalje pruža najpouzdaniju osnovu za dijagnozu.

Aktivnost bolesti procenjuje se na osnovu Birmingham skale aktivnosti vaskulitisa iz 2008. godine, verzija 3 (8), a izabrani modalitet lečenja zavisi od procene težine vaskulitisa prema Vodiču evropske studije o vaskulitisu (9). Za teže oblike oboljenja preporučuje se režim koji se sastoji od glukokortikoida u kombinaciji sa ciklofosfamidom ili rituksimabom. Rituksimab (anti CD20 monoklonalno antitelo) je efikasan kao ciklofosfamid u postizanju remisije kod pacijenata sa novodijagnostikovanim ili relapsom GPA (10, 11). Stope ozbiljnih neželjenih događaja su slične sa oba leka i trenutno ne postoji generalizovani zaključak o početnom imunosupresivnom režimu.

Endokrine disfunkcije tokom GPA smatraju se neuobičajenim, pri čemu prominira centralni dijabetes insipidus (DI), sa oko 10 objavljenih slučajeva u literaturi (12–15). Centralni DI nastaje sekundarno zbog granulomatozne infiltracije posthipofize i/ili stalka hipofize. Centralni dijabetes insipidus može biti prva klinička manifestacija GPA, kao što ilustruju zapažanja Al-Fakhraoui A i dr. (16), a neki autori procenjuju učestalost zahvatanja hipofize tokom GPA od 1% (17) do 1,3% (18). Zahvaćenost testisa može biti prisutna i kod odraslih i pedijatrijskih oblika GPA (19–21). Takođe,

klinička slika obuhvata i primarni hiperparatiroidizam ili češće hiperparatiroidizmu sličnu kliničku sliku kao posledicu hiperkalcemije izazvane ektopičnom aktivacijom D vitamina usled hiperaktivnosti makrofaga u GPA granulomima (22, 23). Švedska studija, na osnovu švedskog „višegeneracijskog” registra, pokazala je da je dijabetes melitus tipa 1 kod potomaka bio značajno povezan sa 13 različitih autoimunih bolesti roditelja, uključujući GPA sa standardizovanim odnosom učestalosti (SIR) od 2,12 (24). Oštećenje parenhima nadbubrežne žlezde granulomatoznim vaskulitisom objavljeno je po prvi put od strane Tomasa GO i Luisa RJ 1979. tokom autopsijskog nalaza muškarca koji je preminuo posle hemoragičnog infarkta nadbubrežne žlezde (25). Važno je napomenuti specifične slučajeve granulomatoznog poliangitisa tokom lečenja Graves-Basedow-ljeve bolesti tireosupresivnom terapijom (propiltiouracil (PTU)) i metimazol (MMI)) (26). Procenjuje se da će  $\approx 25\%$  pacijenata sa Graves-ovom bolešću lečenih PTU razviti ANCA antitela, a neki od pacijenata će razviti pravi sistemski vaskulitis povezan sa ANCA uključujući GPA (27, 28).

Na osnovu podataka iz literature, zahvaćenost štitaste žlezde WG je izuzetno redak događaj. Velika studija na 158 pacijenata, koju su uradili Hoffman i saradnici, nije otkrila dokaze o zahvaćenosti štitaste žlezde (29). Cordier i saradnici su u uzorku od 77 pacijenata zabeležili jedan slučaj hipotireoze, ali štitasta žlezda nije histološki evaluirana (30). Koliko nam je poznato, do danas postoji samo jedan dobro dokumentovan slučaj WG u štitastoj žlezdi, o čemu su nedavno izvestili Šuerverg i saradnici (31). Njihovo istraživanje naglašava da WG treba da bude uzeta u obzir u diferencijalnoj dijagnozi inflamatornih lezija štitaste žlezde. WG, sa pojavom dobro formiranih granuloma, treba razlikovati od drugih oblika granulomatoznog tiroiditisa. Granulomatozne lezije, uključujući dobro formirane granulome, mogu se videti u slučajevima subakutnog granulomatoznog tiroiditisa, takozvanog bolnog tiroiditisa, infekcije (tuberkuloza), sarkoidoze, histiocitne reakcije blizu krvarenja u hiperplastičnim čvorovima ili tumorima, reakcije stranog tela i vaskulitisa. Nasuprot subakutnom granulomatoznom tiroiditisu i bolnom tiroiditisu, infektivni granulomi i granulomatozni vaskulitis se vrlo retko vidaju. Štitasta žlezda može biti ciljani organ bilo kog oblika sistemskog vaskulitisa. Opisani su slučajevi izazvani sistemskim vaskulitisom preosetljivosti na farmakološke agense (npr. fenitoin i fenilhidantoin) (32, 33). Rana faza De Quervain-ovog tiroiditisa može da se prezentuje mikroapscesima, što takođe može biti i deo prezentacije WG. U cilju diferencijalne dijagnoze neophodna je pažljiva obrada patološkog uzorka, posebno u periferiji nekrotizirajućeg granulomatoznog zapaljenja.

Koegzistencija autoimune bolesti štitaste žlezde i ANCA vaskulitisa malih krvnih sudova (engl. SVV, small vessel vasculitis) je opisana u maloj seriji slučajeva sa MPO-ANCA SVV (34) i u nekoliko studija slučajeva (35, 36). Opisani su slučajevi pacijenata sa ANCA SVV koji su dijagnostikovani, istovremeno ili sekvencijalno, sa drugim autoimunim bolestima, uključujući reumatoidni artritis (37), sistemski lupus

(38), Sjogrenov sindrom (39), miastenui gravis (40). Činjenica da se nekoliko različitih autoimunih bolesti mogu javiti među članovima porodice podržava postojanje zajedničke genetske odrednice. Polimorfizam citotoksičnog T limfocitnog antigena-4 (CTLA-4) je povezan sa autoimunim tiroiditisom (41, 42), kao i Wegenerova granulomatoza, što ukazuje na potencijalnu genetsku predispoziciju za autoimunost. U kohorti od 218 pacijenata sa autoimunim oboljenjem tiroidee utvrđeno je da 14% ima sistemsku autoimunu bolest (42). U drugoj studiji, od 426 pacijenata sa Hašimoto tiroiditisom ili Graves-ovom bolešću 30% je imalo drugi oblik autoimune bolesti; 51% među onima sa hroničnim tiroiditisom i 16% među onima sa Grejvsovom bolešću (43). Prikazan je odnos između AIT i ANCA vaskulitisa u radovima Lionaki i sardnika (44). Pokazano je da je kada je dijagnostikovano ANCA vaskulitis čak 40% žena imalo oboljenje štitne žlezde. Među muškarcima, prevalencija bolesti štitne žlezde bila je znatno niža. Pacijenti sa pozitivnom anamnezom za bolesti štitaste žlezde imaju veću verovatnoću da će imati mieloperoksidazu (MPO)-ANCA (86%) nego proteinazu 3-ANCA (14%). I genetska predispozicija i unakrsna reaktivnost između antigena su pretpostavljeni kao potencijalni mehanizmi. Funkcionalni polimorfizam u genu tirozin fosfataze, alel PTPN22 620V, prepoznat je kao predisponirajući faktor za nekoliko autoimunih bolesti, uključujući Grejvsovu bolest i hronični tiroiditis (45), a nedavno i Wegenerovu granulomatozu i ANCA pozitivnost (46). PTPN22 se nalazi na hromozomu 1p13.3–13.1.10 i kodira protein od 807 aminokiselina koji je u interakciji sa tirozin kinazom, koja je uključena u intracelularnu kaskadnu signalizaciju nakon aktivacije T-ćelija. Missense varijacija u alelu koji predisponira autoimunost dovodi do povećanja funkcije, što povećava prag za signalizaciju receptora T-ćelija (47).

Čak i kod genetski predisponiranih pojedinaca verovatno je da faktori životne sredine, uključujući i profesionalnu izloženost i izloženost infekcijama, igraju ulogu u autoimunom fenotipu. Izloženost brojnim faktorima životne sredine, kao što je silicijum (48), i infektivnim agensima, kao što je *Staphylococcus aureus* (49), ima ulogu u razvoju ANCA SVV, dok se za izloženost *Iersinia enterocolitica* ili retrovirusima pretpostavlja da učestvuju u patogenezi autoimune bolesti štitne žlezde (50). Međutim, velike studije koje bi donele zaključak o interakciji gen-sredina i patogenetskim mehanizmima u okviru specifičnih autoimunih bolesti nedostaju.

## Literatura

1. Holl-Ulrich K. Vasculitis: New nomenclature of the Chapel Hill consensus conference 2012. *Z Rheumatol.* 2014; 73: 823–833.
2. Karras A, Guiard E, Levi C, Thervet E. Granulomatosis with polyangiitis (Wegener's granulomatosis). *Presse Med.* 2012; 41: 1014–1023.
3. Burns P, Keogh IJ, Waheed K, Timon CV. Wegener's granulomatosis masquerading as unilateral sinusitis. *Ir Med J.* 2004 Feb; 97(2): 51.

4. Abdou NI, Kullman GJ, Hoffman GS, et al. Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. *J Rheumatol.* 2002; 29: 309–16.
5. Mahr AD. Epidemiological features of Wegener's granulomatosis and microscopic polyangiitis: two diseases or one 'anti-neutrophil cytoplasm antibodies-associated vasculitis' entity? *APMIS Suppl.* 2009; 127: 41–7.
6. Grisaru S, Yuen GW, Miettunen PM, Hamiwka LA. Incidence of Wegener's granulomatosis in children. *J Rheumatol.* 2010; 37: 440–2.
7. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. *Arthritis Rheum.* 2005; 53: 93–9.
8. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) *Ann. Rheum. Dis.* 2009; 68: 1827–1832.
9. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. *Ann. Rheum. Dis.* 2009; 68: 310–317.
10. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N. Engl. J. Med.* 2010; 363: 221–232.
11. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N. Engl. J. Med.* 2010; 363: 211–220.
12. van Durme CM, Kisters JM, van Paassen P, van Etten RW, Tervaert JW. Multiple endocrine abnormalities. *Lancet* 2011; 378: 540.
13. Khalifa M, BenFredj H, Ghannouchi N, Sriha B, Letaief A, et al. Thyroid involvement in Wegener's granulomatosis: a case report. *Rev Med Interne.* 2009; 30: 176–178.
14. Garovic VD, Clarke BL, Chilson TS, Specks U. Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. *Am J Kidney Dis.* 2001; 37: E5.
15. Santoro SG, Guida AH, Furioso AE, Glikman P, Rogozinski AS. Panhypopituitarism due to Wegener's granulomatosis. *Arq Bras Endocrinol Metabol.* 2011; 55: 481–485.
16. Al-Fakhouri A, Manadan A, Gan J, Sreih AG. Central diabetes insipidus as the presenting symptom of granulomatosis with polyangiitis. *J Clin Rheumatol.* 2014; 20: 151–154.
17. De Parisot A, Puéchal X, Langrand C, Raverot G, Gil H, et al. Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. *Medicine (Baltimore)* 2015; 94: e748.
18. Kapoor E, Cartin-Ceba R, Specks U, Leavitt J, Erickson B, et al. Pituitary dysfunction in granulomatosis with polyangiitis: The Mayo Clinic experience. *J Clin Endocrinol Metab.* 2014; 99: 3988–3994.
19. Paik ML, MacLennan GT, Seftel AD. Embolic testicular infarction secondary to nonbacterial thrombotic endocarditis in Wegener's granulomatosis. *J Urol.* 1999; 161: 919–920.
20. Agraharkar M, Gokhale S, Gupta R. Wegener's granulomatosis diagnosed by testicular biopsy. *Int Urol Nephrol.* 2002; 34: 559–564.

21. Barber TD, Al-Omar O, Poulik J, McLorie GA. Testicular infarction in a 12-year-old boy with Wegener's granulomatosis. *Urology*. 2006; 67: 846.
22. Edelson GW, Talpos GB, Bone HG 3<sup>rd</sup>. Hypercalcemia associated with Wegener's granulomatosis and hyperparathyroidism: etiology and management. *Am J Nephrol*. 1993; 13: 275–277.
23. Shaker JL, Redlin KC, Warren GV, Findling JW. Case report: hypercalcemia with inappropriate 1,25-dihydroxyvitamin D in Wegener's granulomatosis. *Am J Med Sci*. 1994; 308: 115–118.
24. Hemminki K, Li X, Sundquist J, Sundquist K. Familial association between type 1 diabetes and other autoimmune and related diseases. *Diabetologia*. 2009; 52: 1820–1828.
25. Thomas GO, Lewis RJ. Adrenal infarction: an unusual complication of Wegener's granulomatosis. *Br J Dis Chest*. 1979; 73: 178–180.
26. Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. *Arthritis Res Ther*. 2005; 7: R1072–1081.
27. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving antithyroid medication. *Eur J Endocrinol*. 2000; 142: 587.
28. Pillinger M, Staud R. Wegener's granulomatosis in a patient receiving propylthiouracil for Graves' disease. *Semin Arthritis Rheum*. 1998; 28: 124–129.
29. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med*. 1992; 116: 488–498.
30. Schuerwegh AJ, Verhelst J, Slabbynck H, Kockx MM, Coolen D. Wegener's granulomatosis presenting as a thyroid mass. *Clin Rheumatol*. 2007; 26: 454–456.
31. Cordier JF, Valeyre D, Guillevin L, Loire R, Brechot JM. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. *Chest*. 1990; 97: 906–912.
32. Schuerwegh AJ, Verhelst J, Slabbynck H, Kockx MM, Coolen D. Wegener's granulomatosis presenting as a thyroid mass. *Clin Rheumatol*. 2007; 26: 454–456.
33. Gaffey CM, Chun B, Harvey JC, Manz HJ. Phenytoin-induced systemic granulomatous vasculitis. *Arch Pathol Lab Med*. 1986; 110: 131–135.
34. Yermakov VM, Hitti IF, Sutton AL. Necrotizing vasculitis associated with diphenylhydantoin: two fatal cases. *Hum Pathol*. 1983; 14: 182–184.
35. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, et al. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. *Nephrol Dial Transplant*. 2007; 22: 3508–15.
36. Afeltra A, Paggi A, De Rosa FG, Manfredini P, Addressi MA, Amoroso A. Antineutrophil cytoplasmic antibodies in autoimmune thyroid disorders. *Endocr Res* 1998; 24: 185–194.
37. Masor JJ, Gal AA, LiVolsi VA. Case report: Hashimoto's thyroiditis associated with Wegener's granulomatosis. *Am J Med Sci*. 1994; 308: 112–114.
38. Draibe J, Salama AD. Association of ANCA associated vasculitis and rheumatoid arthritis: a lesser recognized overlap syndrome. *Springerplus*. 2015 Feb 1; 4:50.

- Hounoki H, Shinoda K, Matsui A, Okumura M, Yamaguchi S, Kakeshita K, Yamazaki H, Koike
39. Makino T, Tobe K. A Case of Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis Overlap Syndrome. *Case Rep Rheumatol.* 2021 Jan 7; 2021: 6690658.
  40. Guellec D, Cornec-Le Gall E, Groh M, Hachulla E, Karras A, Charles P, Dunogué B, Abad S, Alvarez F, Gérard F, Devauchelle-Pensec V, Pers JO, Puéchal X, Guillevin L, Saraux A, Cornec D; CRI (Club Rhumatismes et Inflammation) and the French Vasculitis Study Group. ANCA-associated vasculitis in patients with primary Sjögren's syndrome: detailed analysis of 7 new cases and systematic literature review. *Autoimmun Rev.* 2015 Aug; 14(8): 742–50.
  41. Raillard-Gohin H, Leray-Moragues H, Canaud B, Pages M. Systemic vasculitis and hyperthyroidism in a patient with myasthenia gravis. *J Neurol* 2001; 248: 525–526.
  42. Brand O, Gough S, Heward J. HLA, CTLA-4 and PTPN22: the shared genetic master-key to autoimmunity? *Expert Rev Mol Med.* 2005; 7: 1–15.
  43. Gaches F, Delaire L, Nadalon S, Loustaud-Ratti V, Vidal E. Fréquence des maladies auto-immunes chez 218 patients atteints de pathologies thyroïdiennes auto-immunes [Frequency of autoimmune diseases in 218 patients with autoimmune thyroid pathologies]. *Rev Med Interne.* 1998 Mar; 19(3): 173–9.
  44. Biró E, Szekanez Z, Czirják L, Dankó K, Kiss E, Szabó NA, Szucs G, Zeher M, Bodolay E, Szegedi G, Bakó G. Association of systemic and thyroid autoimmune diseases. *Clin Rheumatol.* 2006 Mar; 25(2): 240–5.
  45. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Nachman PE. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study, *Nephrol DialTransplant*, 2007 Dec; 22(12): 3508–3515.
  46. Conzuelo Rodríguez G, Mendieta Zerón H. Familial autoimmune thyroid disease and PTPN-22. *Med Glas (Zenica).* 2015 Aug; 12(2): 151–6.
  47. Martorana D, Maritati F, Malerba G, Bonatti F, Alberici F, Oliva E, et al. PTPN22 R620W polymorphism in the ANCA-associated vasculitides. *Rheumatology (Oxford)* 2012; 51: 805–12.
  48. Bottini N, Peterson EJ. Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease. *Annu Rev Immunol.* 2014; 32: 83–119.
  49. Hogan SL, Cooper GS, Savitz DA, Nylander-French L, Parks CG, Chin H, Jennette CE, Lionaki S, Jennette CE, Falk RJ. Association of Silica Exposure with Anti-Neutrophil Cytoplasmic Autoantibody Small-Vessel Vasculitis: A Population-Based, Case-Control Study *CJASN* Mar 2007; 2(2): 290–299.
  50. Salmela A, Rasmussen N, Tervaert JWC, Jayne DRW, Ekstrand A. European Vasculitis Study Chronic nasal *Staphylococcus aureus* carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate *Rheumatology* 2017; 56: 965–972.
  51. Corapçıoğlu D, Tonyukuk V, Kiyani M, Yilmaz AE, Emral R, Kamel N, et al. Relationship between thyroid autoimmunity and *Yersinia enterocolitica* antibodies. *Thyroid.* 2002; 12: 613–7.



---

Marija Miletić<sup>1</sup>, Miloš Stojanović<sup>1</sup>, Mirjana Stojković<sup>1</sup>, Biljana Nedeljković Beleslin<sup>1</sup>, Milina Tančić Gajić<sup>1</sup>, Jasmina Ćirić<sup>1</sup>, Miloš Žarković<sup>1</sup>

## GRANULOMATOSIS WITH POLYANGIITIS – POSSIBLE ENDOCRINE MANIFESTATIONS

**Abstract:** Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a necrotizing vasculitis of small and medium-sized blood vessels characterized by diffuse inflammation of vascular structures and perivascular and extravascular granulomatosis. In its systemic form, GPA predominantly affects the ear, nose and throat, with lung and kidney involvement with typically rapidly progressive necrotizing glomerulonephritis with extracapillary crescents, while the absence of kidney damage at the time of diagnosis is defined as a limited form of GPA with a more favorable prognosis (1, 2). Antineutrophil cytoplasmic antibodies (c-ANCA) with specificity for proteinase 3 (PR3) represent a biochemical diagnostic criterion. They are detected in 90% of generalized forms and in about 50% of limited forms of granulomatosis with polyangiitis (1, 2). In the absence of treatment, GPA is a disease of progressive evolution. Systemic corticosteroid therapy and immunosuppressive therapy significantly changed the prognostic aspect of the disease. Only a few sporadic observations have been published on endocrine disorders associated with GPA. We present a case of a man, 39 years old, with Wegener’s granulomatosis who developed autoimmune thyroiditis 8 years after the initial diagnosis.

**Key words:** Granulomatosis with polyangiitis, autoimmune thyroiditis, antineutrophil cytoplasmic, antibodies small vessel vasculitis

### *Introduction*

Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a necrotizing vasculitis of small and medium-sized blood vessels characterized by diffuse inflammation of vascular structures and perivascular and

---

<sup>1</sup> University Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center Serbia, drmariamiletic@gmail.com

extravascular granulomatosis. In its systemic form, GPA predominantly affects the ear, nose and throat, with lung and kidney involvement with typically rapidly progressive necrotizing glomerulonephritis with extracapillary crescents, while the absence of kidney damage at the time of diagnosis is defined as a limited form of GPA with a more favorable prognosis (1, 2). Antineutrophil cytoplasmic antibodies (c-ANCA) with specificity for proteinase 3 (PR3) represent a biochemical diagnostic criterion. They are detected in 90% of generalized forms and in about 50% of limited forms of granulomatosis with polyangiitis (1, 2). In the absence of treatment, GPA is a disease of progressive evolution. Systemic corticosteroid therapy and immunosuppressive therapy significantly changed the prognostic aspect of the disease. Only a few sporadic observations have been published on endocrine disorders associated with GPA.

### ***Case presentation***

MN, 39 years old, was hospitalized for the first time in the University Clinic of Pulmonology 8 years ago, after radiographic changes in the lungs on both sides. Complaints occurred in the form of nosebleeds, migrating pain in the joints, weakness, difficulty in swallowing solid food. An ENT examination diagnosed erosive rhinitis, and *Staphylococcus aureus* was detected in a nasal swab. Microhematuria present in urine sediment. MDCT of the chest showed multiple focal changes up to 30 mm in diameter, in the right basal zone of parenchymal condensation according to the type of subsegmental atelectasis. Performed immunological analyzes that confirmed Wegener's granulomatosis, c ANCA 1:320, antiPR3At 100. Angiotensin converting enzyme, tumor markers, serological viral markers were within reference values. Therapy with pulse doses of cyclophosphamide and glucocorticoids was introduced, he received 6 cycles, after which oral therapy was started. Control visualization of the lungs showed a progressive course, after which the patient received two cycles of immunoglobulin therapy, and further treatment continued with oral Methotrexate, folic acid and oral glucocorticoid therapy with gradual dose reduction. Due to the increase in PR3At, ANCA c and CRP, along with a stationary NMR lung finding and the absence of complaints, a whole-body positron emission tomography (FDG PET/CT) was performed, which showed increased FDG binding in the thyroid gland, diffuse and moderate (SUV max 4.7 in the right, SUV max 3.3 in the left lobe, discrete binding at the level of multiple changes in the lungs bilaterally (SUV max up to 1.9, in the surrounding lung tissue SUV max 1.1). In the family history, the mother had a thyroidectomy due to goiter. ECHO of the thyroid gland: properly laid thyroid, normal size, pseudonodular, heterogeneous, changed according to the type of chronic thyroiditis, without identifying cystic or solid changes. Biochemical analyzes were normal, as was the assessment of renal function. Hormonal analyses: thyrotropin hormones (TSH) 4.4 m IU/L, free thyroxine (FT4) 9.9 ng/l, antithyroid peroxidase

antibodies 37.09 IU/ml, antithyroglobulin antibodies 124.2 IU/ml, follicle stimulating hormone (FSH) 2.6 IU/L, luteotropic hormone (LH) 3.2 IU/L, testosterone (T) 13.39 nmol/l, PRL 314 m IU/L, dehydroepiandrosterone (DHEA-S) 5.7 mmol/l, vitamin D 95 nmol/l, PTH 50 ng/l. Therapy with inositol preparations was introduced, with monitoring of thyroid function in 3 months.

## ***Discussion***

Granulomatosis with polyangiitis (GPA, Wegener's granulomatosis) is an idiopathic systemic disease that classically manifests as a triad of upper and lower respiratory tract involvement with glomerulonephritis (3). The most common symptoms are nonspecific and include fever, malaise, cough, weight loss, chest pain, and hemoptysis. The prevalence of WG was estimated at 23.7–156.5: 1000000 (4, 5), with an annual incidence of 3.0–14.4: 1000000 (6, 7).

Antineutrophil cytoplasmic autoantibodies (ANCA) are a serological determinant of GPA. ANCA are mainly directed against proteinase 3 (PR3-ANCA). Sinusitis is the most common initial presentation in about half to two thirds of patients with VG (3). Lung and kidney involvement are classic manifestations of WG, and ocular manifestations occur in 28% to 58% of patients with WG. Other rather uncommon presentations of WG include salivary gland, skin, gastrointestinal, and cardiac involvement. The disease can occur at any age, but the peak incidence is in early middle age. It occurs somewhat more often in men. Untreated, the disease is associated with a very poor prognosis. Although ANCAs are found in most patients with WG, histopathological analysis still provides the most reliable basis for diagnosis.

Disease activity is assessed based on the Birmingham Vasculitis Activity Scale from 2008, version 3 (8), and the chosen treatment modality depends on the assessment of the severity of vasculitis according to the European Vasculitis Study Guide (9). For more severe forms of the disease, a regimen consisting of glucocorticoids in combination with cyclophosphamide or rituximab is recommended. Rituximab (anti CD20 monoclonal antibody) is as effective as cyclophosphamide in achieving remission in patients with newly diagnosed or relapsed GPA (10, 11). The rates of serious adverse events are similar with both drugs and there is currently no generalizable conclusion about the initial immunosuppressive regimen.

Endocrine dysfunctions during GPA are considered uncommon, with central diabetes insipidus (DI) prominent, with about 10 published cases in the literature (12–15). Central DI occurs secondary to granulomatous infiltration of the hypophysis and/or pituitary stalk. Central diabetes insipidus may be the first clinical manifestation of GPA as illustrated by the observations of Al-Fakhouri A et al. (16), and some authors estimate the frequency of involvement of the pituitary gland during GPA from 1% (17) to 1.3% (18). Testicular involvement can be present in both adult and pediatric

forms of GPA (19–21). Also, the clinical picture includes primary hyperparathyroidism or, more often, a clinical picture similar to hyperparathyroidism as a consequence of hypercalcemia caused by ectopic activation due to hyperactivity of macrophages in GPA granulomas (22, 23). A Swedish study, based on a Swedish “multigenerational” registry, showed that type 1 diabetes mellitus in offspring was significantly associated with 13 different parental autoimmune diseases including GPA with a standardized incidence ratio (SIR) of 2.12 (24). Damage to the adrenal parenchyma by granulomatous vasculitis was first reported by Thomas GO and Lewis RJ in 1979 during the autopsy of a man who died after hemorrhagic adrenal infarction (25). It is important to note specific cases of granulomatous polyangiitis during the treatment of Graves-Basedow disease with thyrosuppressive therapy (propylthiouracil (PTU) and methimazole (MMI)) (26). It is estimated that  $\approx 25\%$  of patients with Graves’ disease treated with PTUs will develop ANCA antibodies, and some patients will develop true ANCA-associated systemic vasculitis including GPA (27, 28).

Based on data from the literature, involvement of the thyroid gland by WG is an extremely rare event. A large study of 158 patients by Hoffman et al found no evidence of thyroid involvement (29). Cordier et al recorded one case of hypothyroidism in a sample of 77 patients, but the thyroid gland was not evaluated histologically (30). To our knowledge, to date there is only one well-documented case of WG in the thyroid gland, which was recently reported by Schuerweg et al (31). Their research emphasizes that WG should be considered in the differential diagnosis of inflammatory thyroid lesions. WG, with the appearance of well-formed granulomas, should be distinguished from other forms of granulomatous thyroiditis. Granulomatous lesions, including well-formed granulomas, can be seen in cases of subacute granulomatous thyroiditis, so-called painful thyroiditis, infection (tuberculosis), sarcoidosis, histiocytic reactions near hemorrhage in hyperplastic nodules or tumors, foreign body reactions, and vasculitis. In contrast to subacute granulomatous thyroiditis and painful thyroiditis, infectious granulomas and granulomatous vasculitis are very rarely seen. The thyroid gland can be a target organ in any form of systemic vasculitis. Cases caused by systemic are described vasculitis of hypersensitivity to pharmacological agents (phenytoin and phenylhydantoin) (32, 33). The early stage of De Quervain’s thyroiditis can present with microabscesses, which can also be part of the presentation of WG. For the purpose of differential diagnosis, careful processing of the pathological sample is necessary, especially in the periphery of necrotizing granulomatous inflammation.

Coexistence of autoimmune thyroid disease and ANCA small vessel vasculitis (SVV) has been described in a small case series of 10 patients with MPO-ANCA SVV (34) and in several case studies (35,36). Cases of patients with ANCA SVV diagnosed concurrently or sequentially with other autoimmune diseases have been described, including rheumatoid arthritis (37), systemic lupus (38), Sjogren’s syndrome (39), and myasthenia gravis (40). The fact that several different autoimmune diseases can occur

in family members supports the existence of a common genetic determinant. Cytotoxic T lymphocyte antigen-4 (CTLA-4) polymorphism has been associated with autoimmune thyroiditis (41, 42) as well as Wegener's granulomatosis, suggesting a potential genetic predisposition to autoimmunity. In a cohort of 218 patients with autoimmune thyroid disease, 14% were found to have systemic autoimmune disease (42). In a study of patients with Hashimoto's thyroiditis or Graves' disease, 30% had another form of autoimmune disease; 51% among those with chronic thyroiditis and 16% among those with Graves' disease (43). The relationship between AIT and ANCA vasculitis was shown in the works of Lionaki et al. (44). It has been shown that when ANCA vasculitis was diagnosed, as many as 40% of women had thyroid disease. Among men, the prevalence of thyroid disease was significantly lower. Patients with a positive history of thyroid disease are more likely to have myeloperoxidase (MPO)-ANCA (86%) than proteinase 3-ANCA (14%) (53). Both genetic predisposition and cross-reactivity between antigens have been postulated as potential mechanisms. A functional polymorphism in the tyrosine phosphatase gene, the PTPN22 620V allele, has been recognized as a predisposing factor for several autoimmune diseases including Graves' disease and chronic thyroiditis (45), and more recently Wegener's granulomatosis and ANCA positivity (46). PTPN22 is located on chromosome 1p13.3–13.1.10 and encodes a protein of 807 amino acids that interacts with a tyrosine kinase involved in an intracellular signaling cascade following T-cell activation. A missense variation in an allele that predisposes to autoimmunity leads to a gain of function that raises the threshold for T-cell receptor signaling (47).

Even in genetically predisposed individuals, it is likely that environmental factors, including occupational and infectious exposures, play a role in the autoimmune phenotype. Exposure to a number of environmental factors such as silicon (48), and infectious agents such as *Staphylococcus aureus* (49) has a role in the development of ANCA SVV, while exposure to *Yersinia enterocolitica* or retroviruses are thought to play a role in pathogenesis of autoimmune diseases of the thyroid gland (50). However, large studies that would draw conclusions about gene-environment interaction and pathogenetic mechanisms within specific autoimmune diseases are lacking.

## ***Literatura***

1. Holl-Ulrich K. Vasculitis: New nomenclature of the Chapel Hill consensus conference 2012. *Z Rheumatol.* 2014; 73: 823–833.
2. Karras A, Guiard E, Levi C, Thervet E. Granulomatosis with polyangiitis (Wegener's granulomatosis). *Presse Med.* 2012; 41: 1014–1023.
3. Burns P, Keogh IJ, Waheed K, Timon CV. Wegener's granulomatosis masquerading as unilateral sinusitis. *Ir Med J.* 2004 Feb; 97(2): 51.

4. Abdou NI, Kullman GJ, Hoffman GS, et al. Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. *J Rheumatol.* 2002; 29: 309–16.
5. Mahr AD. Epidemiological features of Wegener's granulomatosis and microscopic polyangiitis: two diseases or one 'anti-neutrophil cytoplasm antibodies-associated vasculitis' entity? *APMIS Suppl.* 2009; 127: 41–7.
6. Grisaru S, Yuen GW, Miettunen PM, Hamiwka LA. Incidence of Wegener's granulomatosis in children. *J Rheumatol.* 2010; 37: 440–2.
7. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. *Arthritis Rheum.* 2005; 53: 93–9.
8. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) *Ann. Rheum. Dis.* 2009; 68: 1827–1832.
9. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. *Ann. Rheum. Dis.* 2009; 68: 310–317.
10. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N. Engl. J. Med.* 2010; 363: 221–232.
11. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N. Engl. J. Med.* 2010; 363: 211–220.
12. van Durme CM, Kisters JM, van Paassen P, van Etten RW, Tervaert JW. Multiple endocrine abnormalities. *Lancet* 2011; 378: 540.
13. Khalifa M, BenFredj H, Ghannouchi N, Sriha B, Letaief A, et al. Thyroid involvement in Wegener's granulomatosis: a case report. *Rev Med Interne.* 2009; 30: 176–178.
14. Garovic VD, Clarke BL, Chilson TS, Specks U. Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. *Am J Kidney Dis.* 2001; 37: E5.
15. Santoro SG, Guida AH, Furioso AE, Glikman P, Rogozinski AS. Panhypopituitarism due to Wegener's granulomatosis. *Arq Bras Endocrinol Metabol.* 2011; 55: 481–485.
16. Al-Fakhouri A, Manadan A, Gan J, Sreih AG. Central diabetes insipidus as the presenting symptom of granulomatosis with polyangiitis. *J Clin Rheumatol.* 2014; 20: 151–154.
17. De Parisot A, Puéchal X, Langrand C, Raverot G, Gil H, et al. Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. *Medicine (Baltimore)* 2015; 94: e748.
18. Kapoor E, Cartin-Ceba R, Specks U, Leavitt J, Erickson B, et al. Pituitary dysfunction in granulomatosis with polyangiitis: The Mayo Clinic experience. *J Clin Endocrinol Metab.* 2014; 99: 3988–3994.
19. Paik ML, MacLennan GT, Seftel AD. Embolic testicular infarction secondary to nonbacterial thrombotic endocarditis in Wegener's granulomatosis. *J Urol.* 1999; 161: 919–920.

20. Agraharkar M, Gokhale S, Gupta R. Wegener's granulomatosis diagnosed by testicular biopsy. *Int Urol Nephrol*. 2002; 34: 559–564.
21. Barber TD, Al-Omar O, Poulik J, McLorie GA. Testicular infarction in a 12-year-old boy with Wegener's granulomatosis. *Urology*. 2006; 67: 846.
22. Edelson GW, Talpos GB, Bone HG 3<sup>rd</sup>. Hypercalcemia associated with Wegener's granulomatosis and hyperparathyroidism: etiology and management. *Am J Nephrol*. 1993; 13: 275–277.
23. Shaker JL, Redlin KC, Warren GV, Findling JW. Case report: hypercalcemia with inappropriate 1,25-dihydroxyvitamin D in Wegener's granulomatosis. *Am J Med Sci*. 1994; 308: 115–118.
24. Hemminki K, Li X, Sundquist J, Sundquist K. Familial association between type 1 diabetes and other autoimmune and related diseases. *Diabetologia*. 2009; 52: 1820–1828.
25. Thomas GO, Lewis RJ. Adrenal infarction: an unusual complication of Wegener's granulomatosis. *Br J Dis Chest*. 1979; 73: 178–180.
26. Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. *Arthritis Res Ther*. 2005; 7: R1072–1081.
27. Gunton JE, Stiel J, Clifton-Bligh P, Wilmschurst E, McElduff A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving antithyroid medication. *Eur J Endocrinol*. 2000; 142: 587.
28. Pillinger M, Staud R. Wegener's granulomatosis in a patient receiving propylthiouracil for Graves' disease. *Semin Arthritis Rheum*. 1998; 28: 124–129.
29. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med*. 1992; 116: 488–498.
30. Schuerwegh AJ, Verhelst J, Slabbynck H, Kockx MM, Coolen D. Wegener's granulomatosis presenting as a thyroid mass. *Clin Rheumatol*. 2007; 26: 454–456.
31. Cordier JF, Valeyre D, Guillevin L, Loire R, Brechot JM. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. *Chest*. 1990; 97: 906–912.
32. Schuerwegh AJ, Verhelst J, Slabbynck H, Kockx MM, Coolen D. Wegener's granulomatosis presenting as a thyroid mass. *Clin Rheumatol*. 2007; 26: 454–456.
33. Gaffey CM, Chun B, Harvey JC, Manz HJ. Phenytoin-induced systemic granulomatous vasculitis. *Arch Pathol Lab Med*. 1986; 110: 131–135.
34. Yermakov VM, Hitti IF, Sutton AL. Necrotizing vasculitis associated with diphenylhydantoin: two fatal cases. *Hum Pathol*. 1983; 14: 182–184.
35. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, et al. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. *Nephrol Dial Transplant*. 2007; 22: 3508–15.
36. Afeltra A, Paggi A, De Rosa FG, Manfredini P, Addressi MA, Amoroso A. Antineutrophil cytoplasmic antibodies in autoimmune thyroid disorders. *Endocr Res* 1998; 24: 185–194.
37. Masor JJ, Gal AA, LiVolsi VA. Case report: Hashimoto's thyroiditis associated with Wegener's granulomatosis. *Am J Med Sci*. 1994; 308: 112–114.

38. Draibe J, Salama AD. Association of ANCA associated vasculitis and rheumatoid arthritis: a lesser recognized overlap syndrome. Springerplus. 2015 Feb 1; 4:50.  
Hounoki H, Shinoda K, Matsui A, Okumura M, Yamaguchi S, Kakeshita K, Yamazaki H, Koike
39. Makino T, Tobe K. A Case of Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis Overlap Syndrome. Case Rep Rheumatol. 2021 Jan 7; 2021: 6690658.
40. Guellec D, Cornec-Le Gall E, Groh M, Hachulla E, Karras A, Charles P, Dunogué B, Abad S, Alvarez F, Gérard F, Devauchelle-Pensec V, Pers JO, Puéchal X, Guillevin L, Saraux A, Cornec D; CRI (Club Rhumatismes et Inflammation) and the French Vasculitis Study Group. ANCA-associated vasculitis in patients with primary Sjögren's syndrome: detailed analysis of 7 new cases and systematic literature review. Autoimmun Rev. 2015 Aug; 14(8): 742–50.
41. Raillard-Gohin H, Leray-Moragues H, Canaud B, Pages M. Systemic vasculitis and hyperthyroidism in a patient with myasthenia gravis. J Neurol 2001; 248: 525–526.
42. Brand O, Gough S, Heward J. HLA, CTLA-4 and PTPN22: the shared genetic master-key to autoimmunity? Expert Rev Mol Med. 2005; 7: 1–15.
43. Gaches F, Delaire L, Nadalon S, Loustaud-Ratti V, Vidal E. Fréquence des maladies auto-immunes chez 218 patients atteints de pathologies thyroïdiennes auto-immunes [Frequency of autoimmune diseases in 218 patients with autoimmune thyroid pathologies]. Rev Med Interne. 1998 Mar; 19(3): 173–9.
44. Biró E, Szekanez Z, Czirják L, Dankó K, Kiss E, Szabó NA, Szucs G, Zeher M, Bodolay E, Szegedi G, Bakó G. Association of systemic and thyroid autoimmune diseases. Clin Rheumatol. 2006 Mar; 25(2): 240–5.
45. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Nachman PE. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study, *Nephrol Dial Transplant*, 2007 Dec; 22(12): 3508–3515.
46. Conzuelo Rodríguez G, Mendieta Zerón H. Familial autoimmune thyroid disease and PTPN-22. Med Glas (Zenica). 2015 Aug; 12(2): 151–6.
47. Martorana D, Maritati F, Malerba G, Bonatti F, Alberici F, Oliva E, et al. PTPN22 R620W polymorphism in the ANCA-associated vasculitides. Rheumatology (Oxford) 2012; 51: 805–12.
48. Bottini N, Peterson EJ. Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease. Annu Rev Immunol. 2014; 32: 83–119.
49. Hogan SL, Cooper GS, Savitz DA, Nylander-French L, Parks CG, Chin H, Jennette CE, Lionaki S, Jennette CE, Falk RJ. Association of Silica Exposure with Anti-Neutrophil Cytoplasmic Autoantibody Small-Vessel Vasculitis: A Population-Based, Case-Control Study CJASN Mar 2007; 2(2): 290–299.
50. Salmela A, Rasmussen N, Tervaert JWC, Jayne DRW, Ekstrand A. European Vasculitis Study Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate Rheumatology 2017; 56: 965–972.
51. Corapçioğlu D, Tonyukuk V, Kiyan M, Yilmaz AE, Emral R, Kamel N, et al. Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies. Thyroid. 2002; 12: 613–7.